Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
- Associated Therapies
- -
Investigate the Effect on the QT/QTc Interval of Repeated and Escalating Doses of AZD3480 During 6 Days
- First Posted Date
- 2008-05-29
- Last Posted Date
- 2008-09-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 75
- Registration Number
- NCT00686179
A Study to Define the ECG Effects of Lixivaptan Compared to Placebo and Moxifloxacin in Healthy Adult Men and Women: A Thorough ECG Study
- First Posted Date
- 2008-05-12
- Last Posted Date
- 2011-06-21
- Lead Sponsor
- CardioKine Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT00675701
- Locations
- 🇺🇸
Research Site 1, Austin, Texas, United States
Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 70
- Registration Number
- NCT00672399
- Locations
- 🇬🇧
Reseach Site, Derriford, Plymouth, United Kingdom
🇬🇧Research Site, Leeds, West Yorkshire, United Kingdom
Guanfacine Immediate-release Electrocardiogram Results (QTc) Study
- Conditions
- Interventions
- First Posted Date
- 2008-05-06
- Last Posted Date
- 2021-06-14
- Lead Sponsor
- Shire
- Target Recruit Count
- 83
- Registration Number
- NCT00672984
- Locations
- 🇺🇸
Charles River Clinical Services Northwest, Inc., Tacoma, Washington, United States
Moxifloxacin vs. Polytrim for Conjunctivitis
- First Posted Date
- 2007-12-27
- Last Posted Date
- 2016-01-18
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 124
- Registration Number
- NCT00581542
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2007-11-28
- Last Posted Date
- 2011-09-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 48
- Registration Number
- NCT00564447
Study Evaluating the Effect of Lecozotan SR on the QTc Interval
- Conditions
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Registration Number
- NCT00499642
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
- Conditions
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 15
- Registration Number
- NCT00460759
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
- Conditions
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2007-04-04
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 132
- Registration Number
- NCT00455806
- Locations
- 🇩🇪
Technical University of Munich, Medical Dept. II, Munich, Germany
🇩🇪Med. Department, Jung-Stilling Krankenhaus, Siegen, Germany
🇩🇪Med. Dept. I, Gastroenterology, University Hospital, Technical University of Dresden, Dresden, Germany
Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy
- Conditions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 644
- Registration Number
- NCT00447304
- Locations
- 🇩🇪
University Hospital Heidelberg, Heidelberg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.